Luis Ostrosky-Zeichner

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
    L Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School Houston, 6431 Fannin MSB 2 112, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 24:654-61. 2005
  2. pmc Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
    Bertrand F Dupont
    Universite Paris Descartes, Hopital Necker Enfants Malades, Centre d Infectiologie Necker Pasteur, 149 rue de Sevres, 75015 Paris, France
    Crit Care 13:R159. 2009
  3. ncbi request reprint 40 years of medical mycology at JAC
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, McGovern Medical School at UTHealth, 6431 Fannin, MSB 2 112, Houston, TX 77030, USA
    J Antimicrob Chemother 71:3327-3329. 2016
  4. pmc Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, 6431 Fannin, MSB 2, 112, Houston, TX 77030, USA
    Crit Care 15:189. 2011
  5. doi request reprint Invasive mycoses: diagnostic challenges
    Luis Ostrosky-Zeichner
    Department of Medicine, University of Texas Health Medical School, Houston, Texas 77030, USA
    Am J Med 125:S14-24. 2012
  6. pmc Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 53:1639-41. 2009
  7. ncbi request reprint Prophylaxis and treatment of invasive candidiasis in the intensive care setting
    L Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Health Science Center at Houston, 6431 Fannin, JFB 1 728, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 23:739-44. 2004
  8. ncbi request reprint Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans
    Luis Ostrosky-Zeichner
    University of Texas Houston Medical School, Houston, TX 77030, USA
    Clin Infect Dis 41:654-9. 2005
  9. doi request reprint Early treatment of candidemia in adults: a review
    Luis Ostrosky-Zeichner
    University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    Med Mycol 49:113-20. 2011
  10. ncbi request reprint Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting
    L Ostrosky-Zeichner
    University of Texas Health Science Center at Houston, 6431 Fannin, MSB 2 112, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 26:271-6. 2007

Detail Information

Publications68

  1. ncbi request reprint International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
    L Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School Houston, 6431 Fannin MSB 2 112, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 24:654-61. 2005
    ..Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia. Large-scale, randomized, controlled trials are warranted...
  2. pmc Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
    Bertrand F Dupont
    Universite Paris Descartes, Hopital Necker Enfants Malades, Centre d Infectiologie Necker Pasteur, 149 rue de Sevres, 75015 Paris, France
    Crit Care 13:R159. 2009
    ..Invasive candidiasis and candidemia are life-threatening nosocomial infections in intensive care patients...
  3. ncbi request reprint 40 years of medical mycology at JAC
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, McGovern Medical School at UTHealth, 6431 Fannin, MSB 2 112, Houston, TX 77030, USA
    J Antimicrob Chemother 71:3327-3329. 2016
    ..We highlight advances in medical mycology as reflected in the past 40 years of JAC...
  4. pmc Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, 6431 Fannin, MSB 2, 112, Houston, TX 77030, USA
    Crit Care 15:189. 2011
    ....
  5. doi request reprint Invasive mycoses: diagnostic challenges
    Luis Ostrosky-Zeichner
    Department of Medicine, University of Texas Health Medical School, Houston, Texas 77030, USA
    Am J Med 125:S14-24. 2012
    ....
  6. pmc Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 53:1639-41. 2009
    ..Anidulafungin improved survival and significantly reduced the number of CFU/g in kidneys and serum beta-glucan levels...
  7. ncbi request reprint Prophylaxis and treatment of invasive candidiasis in the intensive care setting
    L Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Health Science Center at Houston, 6431 Fannin, JFB 1 728, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 23:739-44. 2004
    ..Recent advances in antifungal therapy, such as development of the azoles and echinocandins, have resulted in excellent prophylactic and therapeutic choices for the management of this problem...
  8. ncbi request reprint Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans
    Luis Ostrosky-Zeichner
    University of Texas Houston Medical School, Houston, TX 77030, USA
    Clin Infect Dis 41:654-9. 2005
    ..Measurement of (1-->3)-beta-D-Glucan (BG) has emerged as an adjunct diagnostic strategy for invasive fungal infections (IFI)...
  9. doi request reprint Early treatment of candidemia in adults: a review
    Luis Ostrosky-Zeichner
    University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    Med Mycol 49:113-20. 2011
    ..To date, no consistent early treatment strategy has evolved. Proof-of-concept studies are needed to assess the role of pre-emptive and empirical therapy in ICU patients and the relevance of BDG as an early marker of infection...
  10. ncbi request reprint Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting
    L Ostrosky-Zeichner
    University of Texas Health Science Center at Houston, 6431 Fannin, MSB 2 112, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 26:271-6. 2007
    ..36, sensitivity 0.34, specificity 0.90, positive predictive value 0.01, and negative predictive value 0.97. The rule may identify patients at high risk of invasive candidiasis...
  11. doi request reprint Combination antifungal therapy: a critical review of the evidence
    L Ostrosky-Zeichner
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Clin Microbiol Infect 14:65-70. 2008
    ..Combination of antifungals with immune modulators is an exciting new research area. Until more data are available, clinicians should approach combination antifungal therapy with caution...
  12. pmc Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method
    Luis Ostrosky-Zeichner
    University of Texas Medical School at Houston, Texas 77030, USA
    Antimicrob Agents Chemother 52:4175-7. 2008
    ..Analysis of a data set showed good correlation between 48- and 24-h MICs, as well as similar outcomes and pharmacodynamic efficacy parameters, except for isolates in the susceptible dose-dependent category, such as Candida glabrata...
  13. doi request reprint Issues in the design and interpretation of antifungal drug trials in the critically ill
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA
    Curr Opin Infect Dis 22:564-7. 2009
    ..This review will focus on clinical trials of antifungals in this setting and the methodological issues surrounding them...
  14. doi request reprint An insight into the antifungal pipeline: selected new molecules and beyond
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, 6431 Fannin, MSB 2 112, Houston, Texas 77030, USA
    Nat Rev Drug Discov 9:719-27. 2010
    ..Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance...
  15. ncbi request reprint Novel approaches to antifungal prophylaxis
    Luis Ostrosky-Zeichner
    Laboratory of Mycology Research, Center for the Study of Emerging and Re Emerging Pathogens, University of Texas, Houston Medical School, 6431 Fannin Street, Houston, TX 77030, USA
    Expert Opin Investig Drugs 13:665-72. 2004
    ..New antifungal agents, such as the echinocandins and the new azoles, are available and have a potential role in antifungal prophylaxis. Future studies should evaluate which strategy is more useful; prophylaxis or pre-emptive therapy...
  16. ncbi request reprint Amphotericin B: time for a new "gold standard"
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, TX, USA
    Clin Infect Dis 37:415-25. 2003
    ..Given their superior safety profiles, these preparations can now be considered suitable replacements for AmBD for primary therapy for many invasive fungal infections in clinical practice and research...
  17. pmc Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States
    Luis Ostrosky-Zeichner
    University of Texas Houston Medical School, Houston, Texas, USA
    Antimicrob Agents Chemother 47:3149-54. 2003
    ....
  18. ncbi request reprint Voriconazole salvage treatment of invasive candidiasis
    L Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Houston Medical School, 6431 Fannin, JFB 1 728, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 22:651-5. 2003
    ..Voriconazole has promise as a salvage agent for the treatment of invasive candidiasis, even in the settings of previous azole therapy and infection due to Candida krusei...
  19. ncbi request reprint New approaches to the risk of Candida in the intensive care unit
    Luis Ostrosky-Zeichner
    Division of Infectious Disease, University of Texas, Houston Medical School, Houston, Texas 77030, USA
    Curr Opin Infect Dis 16:533-7. 2003
    ..This review focuses on recent advances in risk identification and the groundwork for prophylaxis of invasive candidiasis in the intensive care setting...
  20. pmc Differential antifungal activity of isomeric forms of nystatin
    L Ostrosky-Zeichner
    Laboratory of Mycology Research, Division of Infectious Diseases, Department of Internal Medicine, University of Texas Houston Medical School, 6431 Fannin, Houston, TX 77030, USA
    Antimicrob Agents Chemother 45:2781-6. 2001
    ..Both MIC measurements and time-kill analysis suggest that peak 2 has considerably less activity, if any at all, against Candida spp. Peak 2 may serve as a reservoir for peak 1...
  21. ncbi request reprint Deeply invasive candidiasis
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Houston Medical School, 6431 Fannin, JFB 1 728, Houston, TX 77030, USA
    Infect Dis Clin North Am 16:821-35. 2002
    ..Some forms of candidiasis (e.g., those with ocular, bone, or heart involvement) require a combined medical and surgical approach...
  22. doi request reprint Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis
    Zekaver Odabasi
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas, Houston Medical School, Houston, TX, USA
    Mycoses 53:438-42. 2010
    ..Our data suggests that survival and microbiological response depend more on drug dosing than on the trailing phenotype of the isolates...
  23. pmc In vitro activity of anidulafungin against selected clinically important mold isolates
    Zekaver Odabasi
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Houston Medical School, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 48:1912-5. 2004
    ....
  24. pmc In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp
    Annie Philip
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Houston Medical School, 6431 Fannin, MSB 2 112, Houston, TX 77030, USA
    Antimicrob Agents Chemother 49:3572-4. 2005
    ..anidulafungin with amphotericin B showed indifference for 16/26 isolates, while anidulafungin with either azole showed a synergy trend for 18/26 isolates. All drug combinations showed indifference for 7/7 Fusarium sp. isolates...
  25. pmc In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates
    Sevtap Arikan
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    J Clin Microbiol 40:1406-12. 2002
    ..In vivo testing in animal models is required for clarification of this issue...
  26. pmc In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results
    Niki I Paphitou
    Laboratory for Mycology Research, Center for the Study of Emerging and Re Emerging Pathogens, Division of Infectious Diseases, University of Texas Houston Medical School, 77030, USA
    Antimicrob Agents Chemother 46:3298-300. 2002
    ..Increased inoculum size and extended incubation time resulted in elevated MICs. Posaconazole and voriconazole exhibited promising antifungal activities...
  27. pmc Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis
    Annie Philip
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Houston Medical School, 77030, USA
    J Clin Microbiol 43:4834-5. 2005
    ..7%, and 93% in the immunocompromised group, respectively. Syscan3 has high negative predictive value...
  28. pmc Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp
    Charles R Sims
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Houston Medical School, Houston, TX 77030, USA
    J Clin Microbiol 44:2105-8. 2006
    ..The disk diffusion zone diameters are highly reproducible and correlate well with both the E-test and the microdilution method, making agar-based methods a viable alternative to microdilution for posaconazole susceptibility testing...
  29. pmc In vitro antifungal susceptibilities of Trichosporon species
    Niki I Paphitou
    Laboratory for Mycology Research, Center for the Study of Emerging and Re Emerging Pathogens, Division of Infectious Diseases, University of Texas Houston Medical School, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 46:1144-6. 2002
    ..The azoles tested appeared to be more potent than amphotericin B. Low minimal fungicidal concentration/MIC ratios were observed for voriconazole, posaconazole, and ravuconazole, suggesting fungicidal activity...
  30. ncbi request reprint Invasive candidiasis in immunocompromised hospitalized patients
    Charles R Sims
    Laboratory of Mycology Research, Division of Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    Arch Med Res 36:660-71. 2005
    ..Research is focusing on better diagnostics and the evaluation of strategies such as prophylaxis in high-risk hosts and pre-emptive therapy...
  31. ncbi request reprint Invasive candidiasis in the intensive care unit
    Sujatha Krishnan
    Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX, USA
    Hosp Pract (1995) 38:82-91. 2010
    ..Treatment options involve an expanding spectrum of antifungals. Knowledge of local epidemiology and the risk factors that predispose patients to this disease are essential for effective patient care in an intensive care setting...
  32. ncbi request reprint Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome
    Zekaver Odabasi
    Laboratory of Medical Mycology, University of Texas Houston Medical School, Houston, TX, USA
    Clin Infect Dis 39:199-205. 2004
    ..The Glucatell serum BG detection assay is highly sensitive and specific as a diagnostic adjunct for IFI...
  33. pmc Disk diffusion-based methods for determining Candida parapsilosis susceptibility to anidulafungin
    Zekaver Odabasi
    Division of Infectious Diseases, University of Texas Houston Medical School, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 47:3018-20. 2003
    ..The comparison was poor unless the disks were prepared by dissolving anidulafungin in 1% dimethyl sulfoxide plus 0.1% Tween 80 and testing on Mueller-Hinton agar flooded with glucose and methylene blue...
  34. pmc Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole
    Madonna J Matar
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Houston Medical School, Houston, Texas 77030
    Antimicrob Agents Chemother 47:1647-51. 2003
    ..The agar-based E-test and disk diffusion methods are reliable alternatives to the NCCLS M27-A2 reference microdilution method for isolates that test susceptible to fluconazole...
  35. ncbi request reprint Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature
    Esteban C Nannini
    Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical School, Houston, Texas, USA
    Diagn Microbiol Infect Dis 46:49-54. 2003
    ....
  36. ncbi request reprint Successful use of amphotericin B lipid complex in the treatment of cryptococcosis
    Larry M Baddour
    Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Infect Dis 40:S409-13. 2005
    ..A mean serum creatinine level decrease of 0.02 mg/dL occurred. ABLC was an effective treatment for cryptococcal infection in immunocompromised patients...
  37. pmc Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting
    John F Mohr
    Division of Infectious Diseases, University of Texas Health Science Center at Houston, 6431 Fannin, MSB 2 112, Houston, TX 77030, USA
    J Clin Microbiol 49:58-61. 2011
    ..Elevated BG levels within the first 3 days need to be further characterized...
  38. pmc Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria
    Brahm H Segal
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Infect Dis 47:674-83. 2008
    ..We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge...
  39. pmc Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients
    John F Mohr
    Division of Infectious Diseases and Center for the Study of Emerging and Re emerging Pathogens, University of Texas Health Science Center, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 48:3151-3. 2004
    ..01). Administration of ITC intravenously just prior to hemodialysis appears to produce adequate systemic exposures of ITC and OH-ITC while allowing dialysis clearance of HP-beta-CD. Studies of multiple administrations are warranted...
  40. ncbi request reprint Differences in beta-glucan levels in culture supernatants of a variety of fungi
    Zekaver Odabasi
    UT Medical School Houston, Texas, USA
    Med Mycol 44:267-72. 2006
    ..The majority of the fungal isolates released high levels of beta glucan. Beta glucan test reactivity appears to be species-specific and this may reflect the beta glucan content of the organism...
  41. doi request reprint Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
    Peter G Pappas
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Clin Infect Dis 48:503-35. 2009
    ..This new information is incorporated into this revised document...
  42. doi request reprint Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA
    Mycoses 54:46-51. 2011
    ..Modification of our original rule resulted in a more inclusive rule for studies...
  43. ncbi request reprint Invasive candidiasis in the intensive care unit
    Luis Ostrosky-Zeichner
    University of Texas Health Science Center at Houston, TX, USA
    Crit Care Med 34:857-63. 2006
    ....
  44. ncbi request reprint Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials
    Niki I Paphitou
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas, USA
    Med Mycol 43:235-43. 2005
    ..Risk-stratified antifungal prophylaxis in the ICU is possible. Validation of these results in other types of ICU is now needed...
  45. pmc Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis
    Charles R Sims
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Health Science Center at Houston, Houston, Texas, USA
    J Clin Microbiol 50:2104-6. 2012
    ..Correlation of BG with clinical outcome was assessed in each patient. BG levels tend to decrease in successfully treated patients and increase in treatment failures. BG levels may be useful as surrogates for outcome evaluation of IC...
  46. pmc Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies
    Gloria N Mattiuzzi
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 50:143-7. 2006
    ..In conclusion, intravenous itraconazole and caspofungin provided similar protection against invasive fungal infection during induction chemotherapy, and both drugs were well tolerated...
  47. ncbi request reprint Cost of a ventilator-associated pneumonia in a shock trauma intensive care unit
    Christine S Cocanour
    University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    Surg Infect (Larchmt) 6:65-72. 2005
    ..As part of a successful performance improvement program in decreasing VAP from 10 VAPs/100 ICU admissions to 2.5 VAPs/100 ICU admissions, we examined the costs associated with VAP...
  48. pmc Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury
    John F Mohr
    Division of Infectious Diseases, University of Texas Health Science Center at Houston, 6431 Fannin, MSB 2 112, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 52:1891-3. 2008
    ..In burn patients, daptomycin at 10 to 12 mg/kg of body weight/day would be required to achieve drug exposures similar to those for healthy volunteers receiving 6 mg/kg...
  49. doi request reprint (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis
    Siraya Jaijakul
    University of Texas Health Science Center at Houston, 77030, USA
    Clin Infect Dis 55:521-6. 2012
    ..1,3)-β-D-glucan (BG) is a biomarker for invasive candidiasis (IC). The usefulness of BG level as a prognostic marker of treatment outcome is not well characterized...
  50. doi request reprint Ventilator-associated pneumonia: a review
    Madiha Ashraf
    Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA
    Hosp Pract (1995) 40:93-105. 2012
    ....
  51. ncbi request reprint Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation
    John F Mohr
    Division of Infectious Diseases and Center for the Study of Emerging and Re emerging Pathogens, University of Texas Health Science Center Houston, TX 77030, USA
    Pharmacotherapy 25:426-8. 2005
    ..Measures to prevent confusion and aid in understanding the differences between lipid and nonlipid formulations of amphotericin B should be implemented...
  52. doi request reprint Current options in antifungal pharmacotherapy
    John Mohr
    Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center, Houston, Texas, USA
    Pharmacotherapy 28:614-45. 2008
    ..Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections...
  53. ncbi request reprint Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002
    John F Mohr
    Division of Infectious Diseases and Center for the Study of Emerging and Re emerging Pathogens, University of Texas Health Science Center Houston, 6431 Fannin, JFB 1 728, Houston, TX, USA
    Int J Antimicrob Agents 24:346-51. 2004
    ..aeruginosa, suggesting that the development of resistance is associated with the use of individual agents, rather than overall antibiotic consumption...
  54. ncbi request reprint Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions
    Melissa D Johnson
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Centre, Box 3306, Durham, NC 27710, USA
    Expert Opin Pharmacother 6:2617-32. 2005
    ..Finally, recommendations are made regarding the design and implementation of future pharmacoeconomic analyses that can help establish the true costs of managing invasive fungal infections in at-risk patient populations...
  55. doi request reprint Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
    Francisco M Marty
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Infect Dis 16:828-37. 2016
    ..We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis...
  56. ncbi request reprint Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center
    Charles R Sims
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Houston Medical School, Houston, Texas 77030, USA
    Arch Med Res 38:90-3. 2007
    ..Zygomycosis is an emerging mycosis of increasing relevance. Limited data exist for outcomes with contemporary therapies...
  57. ncbi request reprint Therapy of common superficial fungal infections
    David B Huang
    Department of Internal Medicine, Division of Infectious Diseases, Baylor College of Medicine, Houston, TX 77030, USA
    Dermatol Ther 17:517-22. 2004
    ..The objective of this review is to provide the practicing dermatologist with the recommended available therapy for the treatment of common superficial fungal infections...
  58. doi request reprint Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis
    John F Mohr
    Division of Infectious Diseases, University of Texas Health Science Center at Houston, Houston, Texas, USA
    Clin Ther 30:152-7. 2008
    ..The prevalence of glucose abnormalities has been reported to be greater in hospitalized patients receiving gatifloxacin than in patients receiving ceftriaxone...
  59. pmc Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species
    Frank C Odds
    Aberdeen Fungal Group, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, United Kingdom
    J Clin Microbiol 42:3475-82. 2004
    ....
  60. pmc Combination antifungal therapy
    Melissa D Johnson
    Departments of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Antimicrob Agents Chemother 48:693-715. 2004
  61. pmc Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro
    Jean Sebastien Ripeau
    Department of Microbiology and Immunology, Faculty of Medicine, University of Montreal, Quebec, Canada
    Antimicrob Agents Chemother 46:3096-100. 2002
    ..These results indicate that caspofungin is rapidly fungicidal against C. albicans, before any suppression of SAP or PLB1 gene expression can occur...
  62. ncbi request reprint Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit?
    Luis Ostrosky-Zeichner
    Crit Care Med 32:2552-3. 2004
  63. pmc Effects of serum on in vitro susceptibility testing of echinocandins
    Zekaver Odabasi
    Marmara University, Tophanelioglu Caddesi, No 13, 34662 Altunizade, Istanbul, Turkey
    Antimicrob Agents Chemother 51:4214-6. 2007
    ..Adding human serum sharply increased the MICs of micafungin and anidulafungin and modestly affected the MIC of caspofungin. The increase in MICs does not appear consistent with the rate of protein binding for the three compounds...
  64. ncbi request reprint Prophylaxis for invasive candidiasis in the intensive care unit: is it time?
    Luis Ostrosky-Zeichner
    Crit Care Med 33:2121-2. 2005
  65. ncbi request reprint Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
    Ernst Rüdiger Kuse
    Klinik für Viszeral und Transplantationschirurgie, Hannover, Germany
    Lancet 369:1519-27. 2007
    ..Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis...
  66. pmc Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei
    Vishnu Chaturvedi
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, 120 New Scotland Ave, Albany, NY 12208, USA
    Antimicrob Agents Chemother 52:1500-2. 2008
    ..All drug combinations yielded MICs lower than the MICs of any two drugs tested singly, and combinations of AMB, PSC, CSP, and VRC were indifferent (no antagonism) by summations of fractional inhibitory concentration...
  67. ncbi request reprint Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
    Peter G Pappas
    Div of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Clin Infect Dis 45:883-93. 2007
    ..The echinocandins have potent fungicidal activity against most Candida species, but there are few data comparing the safety and efficacy of echinocandins in the treatment of invasive candidiasis...
  68. ncbi request reprint Medical order formatting in the era of patient safety
    Luis Ostrosky-Zeichner
    Crit Care Med 32:882-3. 2004